Sophisticated BCP for Mycobacteria

Mycobacterial Understanding Through Advanced BCP

Crafted at Linnaeus Bioscience in collaboration with the TB Drug Accelerator (TBDA) and supported by the Bill and Melinda Gates Foundation, MycoBCP is a specialized bacterial cytological profiling (BCP) platform integrated with artificial intelligence, meticulously developed for Mycobacterium tuberculosis (Mtb). MycoBCP is designed to offer a unique perspective in mechanism of action (MOA) research. By comparing the phenotypic outcomes of diverse treatments and drugs with our expansive database, we offer precise classifications based on their biological impacts, revealing profound insights into the cellular and sub-cellular effects of compounds on mycobacteria.

Our AI-driven platform boasts an extensive and continuously expanding library of phenotypes, providing a comprehensive basis for comparison. The inherent capability of the platform to quantify the resemblance between unknown and known phenotypes—or even between unknowns—ensures the acquisition of critical insights even on the most novel compounds. MycoBCP aids in dissecting complex mycobacterial behavior, offering practical solutions and actionable insights for developing more effective anti-tuberculosis strategies.

Collaborative and Innovative Solutions

While MycoBCP is engineered for high throughput, it achieves optimum results when deployed in close collaboration with our partners. We are dedicated to mutual learning and advancement and welcome partnerships to explore the potential and applicability of our platform to meet diverse needs. While MycoBCP has been optimized for use with Mtb, the most notoriously difficult to study of the mycobacterial species, Linnaeus Bioscience has also developed BCP platforms for other mycobacteria such as M. avium and M. smegmatis. Reach out to us to discover how MycoBCP can be tailored to fulfill your specific requirements and drive your research endeavors to new heights.